Completed PHASE3 INTERVENTIONAL 3-arm NCT00764790

Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children

Immunogenicity and Safety of GSK Biologicals' Thimerosal-free TIV Flu Vaccine Versus a Licensed Comparator in Children

Sponsor: GlaxoSmithKline

Conditions Influenza

Updated 9 times since 2017 Last updated: Jul 2, 2018 Started: Oct 1, 2008 Primary completion: Mar 5, 2009 Completion: Jun 1, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Influenza and is currently completed. GlaxoSmithKline leads this study, which shows 9 recorded versions since 2008 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

9 versions recorded

Oct 2025 — Present [monthly]

Completed PHASE3
Sep 2025 — Oct 2025 [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

Aug 2018 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Aug 2018 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Oct 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Arkansas City, United States , Austin, United States , Austintown, United States , Bangkok, Thailand , Bardstown, United States , Benton, United States , Birmingham, United States , Boone, United States , Bossier City, United States , Bountiful, United States and 57 more locations